Bacterial coinfection following a respiratory viral infection is one of the main causes of morbidity and mortality during viral pandemics. However, the specific interaction between S. pneumoniae and ...

A new study found COVID-19 was linked to a significant increase in dementia in older people with type 2 diabetes. The retrospective study published in Frontiers in Aging Neuroscience included a cohort...

SARS-CoV-2 Variant B.1.617 Real Time PCR Kit Variant-specific molecular tests are procurement decisions tied to circulating lineages, platform validation, and local registration. The Bioperfectus kit's listed CE-IVD status and mutation targets define its intended niche, not its universal fit. Variant-specific PCR kits occupy a narrow section of the diagnostic supply chain. They must align with circulating lineages, the laboratory's extraction and amplification platforms, and the regulatory route required in each market.

SARS-CoV-2 Variant Omicron Real Time PCR Kit Variant-specific PCR testing depends less on a single kit than on the full sample-to-result workflow and the evidence package that supports regulatory acceptance. Variant surveillance and diagnostic labs need assays whose declared targets and regulatory status can be checked against local requirements before adoption. The Bioperfectus SARS-CoV-2 Variant Omicron Real Time PCR Kit is listed with CE-IVD status and a defined target set.

Bacterial coinfection following a respiratory viral infection is one of the main causes of morbidity and mortality during viral pandemics. However, the specific interaction between S. pneumoniae and ...

SARS-CoV-2 Variant Lambda (C.37) Real Time PCR Kit Variant-specific molecular assays are only useful when their targets match current surveillance needs and their claims hold up under local regulatory review. The Bioperfectus Lambda C.37 kit sits in that narrow procurement space. The SARS-CoV-2 Variant Lambda (C.37) Real Time PCR Kit is a Bioperfectus laboratory product for molecular diagnostic testing related to the Lambda variant.

A new study by researchers from the University of Pécs in Hungary has uncovered a striking association between autoimmune antibodies linked to rheumatoid arthritis and significantly lower levels of SARS-CoV-2-specific immunoglobulin G (IgG), an important antibody involved in the immune response against COVID-19. New research from Hungary links rheumatoid arthritis-associated autoimmune...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants pose persistent global public health challenges. Understanding variant-specific viral uncoating mechanisms, a rate-limiting infect...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants pose persistent global public health challenges. Understanding variant-specific viral uncoating mechanisms, a rate-limiting infection step, is critical for antiviral development. The nucleocapsid (N) protein is essential for viral RNA packaging and replication, but how its mutations regulate ribonucleocapsid disassembly remains unclear, with technical barriers hindering real-time biosafe visualization. We developed a versatile dual-labeled fluorescent trans-complemented virus-like particle (DL-trVLP) system enabling single-virus tracking of viral RNA and N protein dynamics under BSL-2 conditions. Our findings show that the circulating R203K/G204R mutation accelerates uncoating and enhances viral RNA accumulation and replication, uncovering a mutation-pathogenicity link. This work advances SARS-CoV-2 lifecycle understanding, provides a valuable research tool, and identifies a key antiviral target for combating variants.

Preparing for the emergence of new respiratory viruses is difficult because vaccines cannot be developed and deployed immediately after an outbreak begins. In a recent study, researchers from Japan found that a vaccine adjuvant called K3-SPG can provide mice with long-lasting, pathogen-independent protection against viruses like influenza A and SARS-CoV-2. The results underscore the potential for adjuvants to be stockpiled and deployed early during outbreaks while specific vaccines are being developed. The COVID-19 pandemic showed the challenges of protecting populations when a new respiratory virus emerges. Although vaccines were developed at unprecedented speed, there was still a period when vaccines were not yet available, and people remained vulnerable to infection. This raises an important question: Could the body's natural defenses be temporarily strengthened without knowing which virus will emerge? One possible answer lies in innate immunity, the body's first line of defense. Unlike adaptive immunity, which learns to recognize specific targets, innate immunity can respond to threats without prior exposure. Some studies have shown that certain stimuli can leave innate immune cells more responsive through a phenomenon called trained immunity. However, questions remain about how long this protection can last and which cells are responsible for maintaining it in the...

Provides general and specific biosafety laboratory guidelines for handling SARS-CoV-2 specimens

In this exploratory randomized trial, the monoclonal antibody AER002 was safe but did not improve clinical or biomarker outcomes in Long COVID. Post-hoc findings suggest baseline antibody levels and d...

In this exploratory randomized trial, the monoclonal antibody AER002 was safe but did not improve clinical or biomarker outcomes in Long COVID. Post-hoc findings suggest baseline antibody levels and d...

The noncanonical functions of PKM2 drive pathogenic T cell function in patients with MS.